Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study
gBRCA1/2m patients could represent a higher-risk population for AIC. gBRCA1/2 status should be one of the factors to consider in deciding on adjuvant anthracycline necessity. This population could benefit from a cardio-oncology closer follow-up and cardioprotective strategies.
Authors
- José Manuel del Rey (ORCID: https://orcid.org/0000-0002-5880-1711)
- Cristina Saavedra (ORCID: https://orcid.org/0000-0002-1063-2306)
- María Fernández-Abad
- Alfonso Cortés-Salgado
- María Gión (ORCID: https://orcid.org/0000-0002-6601-3360)
- Diana Isabel Rosero
- Gonzalo Luis Alonso Salinas (ORCID: https://orcid.org/0000-0001-5914-8526)
- Pilar Agudo-Quílez
- Pilar Garrido (ORCID: https://orcid.org/0000-0002-5899-6125)
- Carmen Guillén‐Ponce (ORCID: https://orcid.org/0000-0002-3594-1084)
- Miriam Menacho
- Elena López-Miranda (ORCID: https://orcid.org/0000-0002-2253-739X)
- Pilar Sotoca
- Noelia Martínez-Jáñez (ORCID: https://orcid.org/0000-0002-0436-0906)
- J.J. Serrano Domingo (ORCID: https://orcid.org/0000-0003-4126-7150)
- Laura del Campo-Albendea
- Jesús Vicente Chamorro
- María Teresa Salazar
- David Cordero Pereda (ORCID: https://orcid.org/0000-0002-9932-7147)
- Eva Guerra
Institutions
- Universidad Pública de Navarra (UPNA) (ES)
- Instituto de Salud Carlos III (ES)
- Navarrabiomed (ES)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Department of Medical Sciences (BY)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Grupo ACS (Spain) (ES)
- Universidad de Navarra (ES)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1093/oncolo/oyae299
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- Instituo Cajal